Abstract
Nanovaccines need to be transported to lymph node follicles to induce humoral immunity and generate neutralizing antibodies. Here, we discovered that subcapsular sinus macrophages play a barrier role to prevent nanovaccines from accessing lymph node follicles. This is illustrated by measuring the humoral immune responses after removing or functionally altering these cells in the nanovaccine transport process. We achieved up to 60 times more antigen-specific antibody production after suppressing subcapsular sinus macrophages. The degree of the enhanced antibody production is dependent on the nanovaccine dose and size, formulation, and administration time. We further found that pharmacological agents that disrupt the macrophage uptake function can be considered as adjuvants in vaccine development. Immunizing mice using nanovaccines formulated with these agents can induce more than 30 times higher antigen-specific antibody production compared to nanovaccines alone. These findings suggest that altering transport barriers to enable more of the nanovaccine to be delivered to the lymph node follicles for neutralizing antibody production is an effective strategy to boost vaccination.
Original language | English |
---|---|
Pages (from-to) | 9478-9490 |
Number of pages | 13 |
Journal | ACS Nano |
Volume | 14 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 25 2020 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:Copyright © 2020 American Chemical Society.
ASJC Scopus Subject Areas
- General Materials Science
- General Engineering
- General Physics and Astronomy
Keywords
- adjuvant
- antibody
- humoral immunity
- lymph node
- macrophage inhibitor
- nanovaccine
- subcapsular sinus macrophages